As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. | About two and a half years after originating the role ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...